Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
You may also be interested in...
MeMed’s test measures immune system response to assess a patient’s COVID-19 trajectory.
Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.
The partnership with the Princess Margaret Cancer Center will support two studies of liquid biopsy testing for lung cancer.